Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Pathology, Research and Practice|February 19, 2017
Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancersMi Jung Kwon, Jeong Won Kim, Jang Yong Jeon, et al.
Oncotarget|November 16, 2017
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resectionMi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, et al.
Biomed Research International|May 22, 2018
Identification of Phosphohistone H3 Cutoff Values Corresponding to Original WHO Grades but Distinguishable in Well-Differentiated Gastrointestinal Neuroendocrine TumorsMin Jeong Kim, Mi Jung Kwon, Ho Suk Kang, et al.
International Journal of Cancer|March 12, 2014
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancerYu Jin Kim, Jong-Sun Choi, Jinwon Seo, et al.
Human Pathology|April 11, 2018
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transitionMi Jung Kwon, Young-Soo Rho, Eun Sook Nam, et al.
Biomaterials|August 12, 2011
Surface camouflage of pancreatic islets using 6-arm-PEG-catechol in combined therapy with tacrolimus and anti-CD154 monoclonal antibody for xenotransplantationJee-Heon Jeong, Sung Woo Hong, Seonki Hong, et al.
Current Oncology (Toronto, Ont.)|May 27, 2022
<i>PIK3CA</i> Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant ChemotherapyYoon Ah Cho, Seung Yeon Ko, Yong Joon Suh, et al.
Journal of Cancer|June 21, 2021
RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancerSung-Hwa Sohn, Hee Jung Sul, Bohyun Kim, et al.
Histology and Histopathology|December 31, 2011
High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patientsSanghui Park, Yoon-La Choi, Chang Ok Sung, et al.
Pathology, Research and Practice|December 25, 2018
Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancerHong Kyu Lee, Mi Jung Kwon, Jinwon Seo, et al.
Pageof 6